FDA — authorised 18 December 2013
- Application: NDA203975
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: ANORO ELLIPTA
- Indication: POWDER — INHALATION
- Status: approved
🇺🇸 Anoro® Ellipta® in United States
FDA authorised Anoro® Ellipta® on 18 December 2013
Marketing authorisation
Anoro® Ellipta® in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory / Pulmonology approved in United States
Frequently asked questions
Is Anoro® Ellipta® approved in United States?
Yes. FDA authorised it on 18 December 2013.
Who is the marketing authorisation holder for Anoro® Ellipta® in United States?
GLAXOSMITHKLINE holds the US marketing authorisation.